Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities research analysts at Wedbush issued their Q2 2017 earnings per share estimates for shares of Corvus Pharmaceuticals in a research note issued on Wednesday. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($0.80) per share for the quarter. Wedbush has a “Outperform” rating and a $26.00 price objective on the stock. Wedbush also issued estimates for Corvus Pharmaceuticals’ Q3 2017 earnings at ($0.85) EPS, Q4 2017 earnings at ($0.62) EPS, FY2017 earnings at ($3.06) EPS, Q1 2018 earnings at ($0.76) EPS, Q2 2018 earnings at ($0.89) EPS, Q3 2018 earnings at ($1.01) EPS, Q4 2018 earnings at ($0.85) EPS, FY2018 earnings at ($3.51) EPS, FY2019 earnings at ($3.49) EPS, FY2020 earnings at ($3.39) EPS and FY2021 earnings at ($3.08) EPS.
Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.73) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.03.
WARNING: “Brokers Issue Forecasts for Corvus Pharmaceuticals, Inc.’s Q2 2017 Earnings (NASDAQ:CRVS)” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2017/08/19/brokers-issue-forecasts-for-corvus-pharmaceuticals-inc-s-q2-2017-earnings-nasdaqcrvs-updated.html.
Shares of Corvus Pharmaceuticals (NASDAQ:CRVS) opened at 11.65 on Monday. The stock has a 50 day moving average price of $12.07 and a 200 day moving average price of $12.92. Corvus Pharmaceuticals has a one year low of $8.27 and a one year high of $22.14. The firm’s market cap is $243.88 million.
A number of hedge funds and other institutional investors have recently bought and sold shares of CRVS. Russell Investments Group Ltd. increased its stake in Corvus Pharmaceuticals by 29.3% in the second quarter. Russell Investments Group Ltd. now owns 9,286 shares of the company’s stock valued at $112,000 after buying an additional 2,105 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in Corvus Pharmaceuticals by 43.3% in the first quarter. TIAA CREF Investment Management LLC now owns 7,181 shares of the company’s stock valued at $149,000 after buying an additional 2,170 shares in the last quarter. Schwab Charles Investment Management Inc. purchased a new stake in Corvus Pharmaceuticals during the second quarter valued at about $212,000. Endurant Capital Management LP purchased a new stake in Corvus Pharmaceuticals during the first quarter valued at about $282,000. Finally, Oxford Asset Management purchased a new stake in Corvus Pharmaceuticals during the first quarter valued at about $287,000. Hedge funds and other institutional investors own 82.66% of the company’s stock.
In other Corvus Pharmaceuticals news, insider Richard A. Md Miller bought 25,000 shares of Corvus Pharmaceuticals stock in a transaction on Tuesday, June 13th. The shares were purchased at an average cost of $9.88 per share, for a total transaction of $247,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Holdings A/S Novo bought 20,000 shares of Corvus Pharmaceuticals stock in a transaction on Friday, June 23rd. The shares were acquired at an average price of $10.95 per share, for a total transaction of $219,000.00. Following the completion of the acquisition, the insider now owns 3,244,046 shares of the company’s stock, valued at approximately $35,522,303.70. The disclosure for this purchase can be found here.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
What are top analysts saying about Corvus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corvus Pharmaceuticals Inc. and related companies.